Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Monitoring SABA dependence
SABA dependence is a key indicator of asthma control. If a patient is using their SABA more than twice per week, it could indicate poor control.*1
Compared with BUD/Form, Relvar is associated with a 10% reduction in SABA use in real-world settings.2
SABA use during 12-months follow-up2
This graph has been independently created by GSK from the original data. The same results were first published in Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.
Discover Relvar
Need help with this product?
Footnotes
*Within the last four weeks. Other important criteria include: daytime symptoms more than twice/week; any night waking due to asthma; any activity limitation due to asthma.
Abbreviations
BUD, budesonide; CI, confidence interval; Form, formoterol; SABA, short-acting β2-agonist.
References
- GINA. Global strategy for asthma management and prevention, 2020. Available at: www.ginasthma.org. Accessed June 2023.
- Averell CM, et al. Presented virtually at the American College of Allergy, Asthma & Immunology annual meeting 2020.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230007 June 2023
